Kenvue, the maker of
Tylenol, has been under intense scrutiny after the
Trump administration made claims linking their product to
autism. This caused significant volatility in the stock price, with substantial plunges and rebounds observed. Key institutions such as
Goldman Sachs and
Barclays have maintained a neutral stance on Kenvue, while cutting their price target. Large stakeholders like
Cullen and
Janney Montgomery Scott LLC have trimmed their holdings, whilst firms like
Truist Financial Corp and
Voya Investment Management LLC have been increasing their stake. Simultaneously, the stock has seen high options volume. Earnings surpassed estimates for Q3, but the company saw a new 52-week low, indicating investor uncertainties. Despite these issues, some voices like
Jim Cramer have been against selling Kenvue at its current price, viewing the downturn as a potential opportunity. Amidst this turmoil, the focus has been on Kenvue's response and the potential long-term value creation.
Kenvue KVUE News Analytics from Mon, 21 Jul 2025 07:00:00 GMT to Sat, 04 Oct 2025 18:08:01 GMT -
Rating -5
- Innovation -3
- Information 0
- Rumor -3
